Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
As I prepare to publish my Year-End/New Year TrendCast for 2026, I felt like front-ending next weeks annual long post with details on the demand side of the forecast a focus on the consumer, patient, caregiver, health citizen
The drugs Ozempic and Wegovy both contain semaglutide, but are dosed differently
If you are experiencing disordered eating or have concerns about your relationship with food, please speak with your provider support is available and this program may not be the right fit.
Clinical trial, 48 weeks: Body weight: -24.2% average Fat loss: significant Lean muscle mass: PRESERVED Metabolic markers: dramatically improved Heres why this is different: Ozempic/Mounjaro = dual agonists (GLP-1 + GIP) Suppress appetite You eat less Lose weight but also muscle Retatrutide = adds glucagon receptor Suppresses appetite AND Activates fat burning directly Body uses fat for fuel instead of breaking down muscle Blood work improvements tracked in trials: Fasting glucose: normalized Triglycerides: -40% Inflammatory markers: reduced Insulin sensitivity: significantly improved The metabolic difference: Dual agonists: Force you to eat less (suffer through hunger, lose muscle) Retatrutide: Reprograms metabolism to PREFER burning fat (appetite controlled, muscle preserved) DEXA scans in the study confirmed: Fat mass dropped dramatically
US$ 27.94
US$ 25.33
US$ 27.46
US$ 27.91
